With the developing knowledge on genetic variants influencing pharmacokinetics and/or pharmacodynamics of frequently applied drugs, multiple providers are now offering PGx assessment using DNA isolated from buccal swaps. In an observational study, we intend to collect patient cases in community and hospital pharmacies, where pharmacogenotyping is applied. Stratipharm (www.stratipharm.de) is a commercial service offering pharmacogenotyping in combination with sophisticated evidence-based interpretation of the genotype. The test system covers almost 100 genetic variants corresponding to 30 genes of pharmacogenetic relevance.

In our case series [ClinicalTrials.gov identifier: NCT04154553; EKNZ Identifier: 2019-01452] over 3 years, the primary objective is the compilation of case reports, where pharmacogenetic testing is applied to determine the hereditable component of the patient’s susceptibility to experience therapy failure and/or adverse drug reactions. The patient receives the results of the pharmacogenotyping in form of a written recommendation to their prescribing physician. The experience with the compiled cases will be basis for the development of a reliable standard operating procedure for pharmacogenetic testing in the community as well as the hospital pharmacy. Therefore, the setup of a training for pharmacists as well as an interprofessional network is crucial.